Screening and Mechanism of Antagonist Peptide for CC Chemokine Receptor 1 (CCR1) Derived from Viral Macrophage Inflammatory Protein II

Li, Sha; Ding, Qing; Wei, Pijin; Sun, Han; Li, Xiuying; An, Guijie; Yang, Yantao; Zhou, Jingguang

doi:10.4314/tjpr.v13i5.7

Cited by 1 publication

(1 citation statement)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proven that vMIP-II has antagonistic activity against CCR1, CCR2B, CCR5, CCR8, CXCR3, and CXCR4, but not against CXCR1 or CXCR2. Its effect on CCR7 has not been clearly reported [6][7][8][9][10][11] . We previously found that vMIP-II competitively inhibits the binding of HIV to the co-receptors CCR5, CXCR4, and CCR3, among others, and used vMIP-II to prevent the virus from entering target cells and to study its role in resisting HIV infection 12,13 .…”

Section: Introductionmentioning

confidence: 98%

Chemokine Receptor Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related Mechanism In Vitro

Li¹,

Wang²,

Feng

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) accompanies severe immune injury as well as a decrease and overactivation of T lymphocytes. We observed that vMIP-Ⅱ, a broad-spectrum chemokine receptor inhibitor, could improve the lymphocyte decrease of COVID-19. Comparisons of T cell populations in PBMCs showed that the effects of vMIP-II on the subsets of T cells and cytokine secretion stimulated by SARS-CoV-2 S protein were the same as those in the asymptomatic infection group: the proportion of CD8+TCM cells in the vMIP-II treatment and asymptomatic groups was significantly higher than that in the symptomatic control group. Differential gene expression of effector CD8+ T cells suggested that vMIP-II inhibits multiple chemokine receptors and related signal pathway and strengthens their stem proliferating capacity. Thus, vMIP-II reconstitutes cellular immunity lost due to acute infection of SARS-CoV-2 by modulating effector CD8+ T cells to produce more TCM cells.

show abstract